Exelon (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Exelon drug offered from Novartis Pharmaceuticals Corporation. This Cholinesterase Inhibitor [EPC],Cholinesterase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | rivastigmine tartrate |
| SUBSTANCE NAME: | RIVASTIGMINE TARTRATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Cholinesterase Inhibitor [EPC],Cholinesterase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | CAPSULE |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2000-04-30 |
| END MARKETING DATE: | 0000-00-00 |
Exelon HUMAN PRESCRIPTION DRUG Details:
| Item Description | Exelon from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 1.5(mg/1) |
| START MARKETING DATE: | 2000-04-30 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0323_995e8f94-ac01-4921-a7fd-fac1d68adc2f |
| PRODUCT NDC: | 0078-0323 |
| APPLICATION NUMBER: | NDA020823 |
Other RIVASTIGMINE TARTRATE Pharmaceutical Manufacturers / Labelers:
